Select Publications
Journal articles
2020, 'Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation', International Journal of Drug Policy, 86, http://dx.doi.org/10.1016/j.drugpo.2020.102964
,2020, 'The 8th Canadian symposium on hepatitis C virus: “improving diagnosis and linkage to care”', Canadian Liver Journal, 3, pp. 3 - 14, http://dx.doi.org/10.3138/canlivj.2019-0032
,2020, 'Adherence to once-daily and twice-daily direct-acting antiviral therapy for Hepatitis C infection among people with recent injection drug use or current opioid agonist therapy', Clinical Infectious Diseases, 71, pp. E115 - E124, http://dx.doi.org/10.1093/cid/ciz1089
,2020, 'Creating an environment for equitable access to direct-acting antiviral therapy for people who inject drugs with hepatitis C', Liver International, 40, pp. 2353 - 2355, http://dx.doi.org/10.1111/liv.14661
,2020, 'Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis', International Journal of Drug Policy, 84, http://dx.doi.org/10.1016/j.drugpo.2020.102866
,2020, 'COVID-19 and the health of people who use drugs: What is and what could be?', International Journal of Drug Policy, 83, http://dx.doi.org/10.1016/j.drugpo.2020.102958
,2020, 'Declining HCV incidence following rapid HCV treatment scale-up in a prison network in Australia: Evidence of treatment as prevention from the SToP-C study', JOURNAL OF HEPATOLOGY, 73, pp. S127 - S127, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587000206&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study', JOURNAL OF HEPATOLOGY, 73, pp. S807 - S808, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587002392&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR', JOURNAL OF HEPATOLOGY, 73, pp. S356 - S356, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587001105&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: Protocol for the CoLAB study', BMJ Open, 10, pp. e034389, http://dx.doi.org/10.1136/bmjopen-2019-034389
,2020, 'Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia', Addiction, 115, pp. 1295 - 1305, http://dx.doi.org/10.1111/add.14941
,2020, 'Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection', Hepatology, 72, pp. 7 - 18, http://dx.doi.org/10.1002/hep.31003
,2020, 'Time to Detection of Hepatitis C Virus Infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis', Journal of Infectious Diseases, 221, pp. 2043 - 2049, http://dx.doi.org/10.1093/infdis/jiaa037
,2020, 'Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial', Health Science Reports, 3, http://dx.doi.org/10.1002/hsr2.151
,2020, 'Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: A retrospective cohort study', Sexual Health, 17, pp. 223 - 230, http://dx.doi.org/10.1071/SH19101
,2020, 'Patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis c virus treatment with directacting antiviral therapies: An international study', Clinical Infectious Diseases, 70, pp. 2369 - 2376, http://dx.doi.org/10.1093/cid/ciz633
,2020, 'Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model', JAMA Network Open, 3, http://dx.doi.org/10.1001/jamanetworkopen.2020.4192
,2020, 'Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials', Liver International, 40, pp. 778 - 786, http://dx.doi.org/10.1111/liv.14266
,2020, 'Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis', Journal of Hepatology, 72, pp. 643 - 657, http://dx.doi.org/10.1016/j.jhep.2019.11.012
,2020, 'Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review', Drug and Alcohol Dependence, 209, http://dx.doi.org/10.1016/j.drugalcdep.2020.107899
,2020, 'Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence', International Journal of Drug Policy, 77, http://dx.doi.org/10.1016/j.drugpo.2019.102656
,2020, 'Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study', Journal of Viral Hepatitis, 27, pp. 281 - 293, http://dx.doi.org/10.1111/jvh.13233
,2020, 'Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting', International Journal of Drug Policy, 77, http://dx.doi.org/10.1016/j.drugpo.2020.102693
,2020, 'Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: A systematic review and meta-analysis', Drug and Alcohol Dependence, 207, http://dx.doi.org/10.1016/j.drugalcdep.2019.107793
,2020, 'Frequency of injecting among people who inject drugs: A systematic review and meta-analysis', International Journal of Drug Policy, 76, http://dx.doi.org/10.1016/j.drugpo.2019.102619
,2020, 'Global elimination of hepatitis C virus by 2030: why not?', Nature Medicine, 26, pp. 157 - 160, http://dx.doi.org/10.1038/s41591-019-0706-x
,2020, 'Associations between housing stability and injecting frequency fluctuations: findings from a cohort of people who inject drugs in Montréal, Canada', Drug and Alcohol Dependence, 206, http://dx.doi.org/10.1016/j.drugalcdep.2019.107744
,2020, 'Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis', The Lancet Global Health, 8, pp. e76 - e91, http://dx.doi.org/10.1016/S2214-109X(19)30462-0
,2020, 'Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—The practitioner experience', Drug and Alcohol Dependence, 206, http://dx.doi.org/10.1016/j.drugalcdep.2019.107705
,2020, 'Prevalence of injecting drug use and coverage of interventions to prevent HIV and hepatitis C virus infection among people who inject drugs in Canada', American Journal of Public Health, 110, pp. 45 - 50, http://dx.doi.org/10.2105/AJPH.2019.305379
,2020, 'Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection', Clinical Infectious Diseases, 70, pp. 123 - 131, http://dx.doi.org/10.1093/cid/ciz162
,2020, 'Frequency of injecting among people who inject drugs: A systematic review and meta-analysis.', Int J Drug Policy, 76, pp. 102619, http://dx.doi.org/10.1016/j.drugpo.2019.102619
,2019, 'A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms', Scientific Reports, 9, http://dx.doi.org/10.1038/s41598-018-35736-2
,2019, 'Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study', Journal of Viral Hepatitis, 26, pp. 1423 - 1430, http://dx.doi.org/10.1111/jvh.13196
,2019, 'Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study', Journal of Viral Hepatitis, 26, pp. 1388 - 1403, http://dx.doi.org/10.1111/jvh.13187
,2019, 'The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination', Clinical Infectious Diseases, 69, pp. 2218 - 2227, http://dx.doi.org/10.1093/cid/ciz714
,2019, '‘Fighting a losing battle’: prisoners’ perspectives of treatment as prevention for hepatitis C with inadequate primary prevention measures', Drugs: Education, Prevention and Policy, 26, pp. 502 - 507, http://dx.doi.org/10.1080/09687637.2018.1494135
,2019, 'The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis', International Journal of Drug Policy, 73, pp. 172 - 184, http://dx.doi.org/10.1016/j.drugpo.2019.07.030
,2019, 'Global patterns of opioid use and dependence: harms to populations, interventions, and future action', The Lancet, 394, pp. 1560 - 1579, http://dx.doi.org/10.1016/S0140-6736(19)32229-9
,2019, 'An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study', International Journal of Drug Policy, 72, pp. 99 - 105, http://dx.doi.org/10.1016/j.drugpo.2019.07.002
,2019, 'Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada', International Journal of Drug Policy, 72, pp. 106 - 113, http://dx.doi.org/10.1016/j.drugpo.2019.03.001
,2019, 'Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all', International Journal of Drug Policy, 72, pp. 1 - 10, http://dx.doi.org/10.1016/j.drugpo.2019.07.016
,2019, 'Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia', Journal of Hepatology, 71, pp. 281 - 288, http://dx.doi.org/10.1016/j.jhep.2019.04.014
,2019, 'Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study', Journal of Viral Hepatitis, 26, pp. 969 - 979, http://dx.doi.org/10.1111/jvh.13112
,2019, 'Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis', International Journal of Drug Policy, 70, pp. 87 - 93, http://dx.doi.org/10.1016/j.drugpo.2019.05.005
,2019, 'Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montréal, Canada', Addiction, 114, pp. 1495 - 1503, http://dx.doi.org/10.1111/add.14632
,2019, 'Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing', Infection, Genetics and Evolution, 71, pp. 36 - 41, http://dx.doi.org/10.1016/j.meegid.2019.02.032
,2019, 'A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus among People Who Inject Drugs - Do Gender-Based Differences Vary by Country-Level Indicators?', Journal of Infectious Diseases, 220, pp. 78 - 90, http://dx.doi.org/10.1093/infdis/jiz058
,2019, 'The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study', The Lancet Gastroenterology and Hepatology, 4, pp. 435 - 444, http://dx.doi.org/10.1016/S2468-1253(19)30085-8
,2019, 'A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections', Infection, Genetics and Evolution, 69, pp. 76 - 84, http://dx.doi.org/10.1016/j.meegid.2019.01.016
,